# OnCo record nct03328078 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03328078/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03328078", "NCT03328078" ;
  schema:name "CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)"@en ;
  schema:description "A phase 1/2 trial of Ibrutinib in brain and spinal cord tumours, run by Curis, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03328078/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03328078> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2017-12-28" ;
  onco:cancers <https://onco.cc/cancers/brain-tumours/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/emavusertib/> ;
  onco:companies <https://onco.cc/companies/curis/> .